Verde Science Adds Lawyer, Bradley J. Dixon, J.D. to Board
LAS VEGAS, NV -- May 20th, 2015 -- InvestorsHub NewsWire
-- (OTCPK: VRCI) Verde Science, Inc., a
Pharmaceutical Research and Development Company focused on
developing effective treatments for contemporary health issues,
with an initial focus on developing cannabinoid-based prescription
medicines is pleased to announce the appointment of Bradley J.
Dixon, J.D. to its Board of Directors. Mr. Dixon is a partner with
the firm of Stoel Rives, LLP, which has offices throughout the
Northwest and California. His professional honors include selection
as one of America’s Leading Lawyers for Business by Chambers USA,
listing in Mountain States Super Lawyers, and admission to the
Order of Barristers. Mr. Dixon’s areas of practice include Business
Law, Government Affairs, Commercial Litigation, and Labor and
Employment Law.
Verde Science CEO, Harp Sangha commented, “As Verde Science
accelerates its development into a more complex international
structure with multiple interconnected facets including research
and product development, intellectual property, and corporate
finance and governance, it has become apparent that participation
from legal professionals is a required input for our strategic and
tactical decision-making. I am proud and excited to have Brad add
his experience in this regard and to be able to benefit from his
business and legal acumen.”
“Harp Sangha has assembled a world-class research and
development team that seems poised to achieve an eminent position
in the medical marijuana field. I am an energetic supporter of
their pharmacological approach that avoids numerous regulatory and
legal pitfalls. I am honored to be a part of this company,”
according to Bradley Dixon.
About Verde Science, Inc. (OTCPK: VRCI)
Verde Science, Inc. (trading symbol VRCI: OTCPK) is an early stage pharmaceutical
organization that has built a research team focused on developing a
portfolio of cannabinoid prescription medicines to meet patient
needs in a wide range of medical conditions. Verde’s scientists
have identified a number of promising areas in which to begin its
immediate R&D program, which will initially be based in India.
The Verde Science team of inter-disciplinary researchers includes
scientists in Bioprocess Engineering, Nanotechnology, Molecular
Biology, Pharmaceutical Sciences and Bio-Medical Devices that is
focused on a streamlined approach to the development of innovative
treatment protocols aimed at capturing considerable market
share.
Information
www.verdescienceinc.com
Louis Silver, Director of Investor Relations
Tel: 1-610-710-1303
lsilver@verdescienceinc.com
Facebook: goo.gl/gxQFZz
Safe Harbor Statements
Certain information contained in this news release constitutes
“forward-looking statements” as such term is used in applicable
United States and Canadian laws. Generally, these forward-looking
statements can be identified by the use of forward-looking
terminology such as “expects” or “does not expect”, “is expected”,
“anticipates” or “does not anticipate”, “plans”, “estimates”,
“intends” or “believes”, or that certain actions, events or results
“may”, “could”, “would”, “might” or “will be taken”, “occur”, or
“be achieved”. Forward-looking statements are based on the
opinions and estimates of management as of the date such statements
are made, and are subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements. Many of
these factors are beyond the Company’s ability to control or
predict. Important factors that may cause actual results to differ
materially and that could impact the Company and the statements
contained in this news release can be found in the Company’s
filings with the SEC. Such risks and other factors include, among
others, the ability to locate and acquire suitable interests in
alternative medicine manufacturing operations on terms acceptable
to the Company, the availability of financing on acceptable terms,
accidents, labor disputes, acts of God and other risks of the
alternative medicine industry including, without limitation, delays
in obtaining governmental approvals or permits, title disputes or
claims limitations on insurance coverage. The Company believes that
the expectations reflected in the forward-looking statements
included in this news release are reasonable; however, no assurance
can be given that these expectations will prove to be correct, and
such forward-looking statements should not be unduly relied upon.
The Company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise.